Literature DB >> 16651722

Effects of L/N-type calcium channel antagonist, cilnidipine on progressive renal injuries in Dahl salt-sensitive rats.

Tomoyuki Konda1, Azusa Enomoto, Akira Takahara, Hiroshi Yamamoto.   

Abstract

The sympathetic nerve activity plays an important role on the renal function through the vasoactive system and the renin-angiotensin system. Although interest in the renal protective effects of anti-sympathetic agents has been increased, there are not enough data to clarify this efficiency. Therefore, we investigated the effects of L/N-type calcium channel antagonist, cilnidipine on progressive renal injury in Dahl salt-sensitive (Dahl S) rats. Male Dahl S rats (6 weeks of age) were fed a high salt (4% NaCl) diet. They were divided into groups with similar blood pressure at 12 weeks of age and they received vehicle (n=7) or cilnidipine (30 mg/kg/d as food admix, n=9) for 8 weeks. Cilnidipine treatment suppressed the increase in systolic blood pressure. Although urinary protein excretion was not influenced, cilnidipine inhibited the increase in blood urea nitrogen and decrease in creatinine clearance. Histological investigation revealed that progression of glomerular sclerosis was inhibited in cilnidipine treatment group. Of notes, cilnidipine reduced plasma norepinephrine level and plasma rennin activity compared with vehicle-treated Dahl S rats. These data indicated that cilnidipine has suppressive effects against progressive renal injury in Dahl S rats. This effect is not only explained by the L-type calcium channel blocking action that lowered blood pressure, but also partially explained by the N-type calcium channel blocking action that lead to suppression of the sympathetic nerve activity and renin-angiotensin system.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16651722     DOI: 10.1248/bpb.29.933

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  9 in total

1.  The N-type and L-type calcium channel blocker cilnidipine suppresses renal injury in Dahl rats fed a high-salt diet.

Authors:  Shizuka Aritomi; Hajime Koganei; Hirotaka Wagatsuma; Akira Mitsui; Tetsuya Ogawa; Kosaku Nitta; Tomoyuki Konda
Journal:  Heart Vessels       Date:  2010-10-05       Impact factor: 2.037

2.  Effect of Shenkang granules on the progression of chronic renal failure in 5/6 nephrectomized rats.

Authors:  Y U Zhang; Nan Zhou; Hongying Wang; Sicen Wang; Jianyu He
Journal:  Exp Ther Med       Date:  2015-03-24       Impact factor: 2.447

3.  Effect of cilnidipine on normal to marginally elevated urine albumin-creatinine ratio in asymptomatic non-diabetic hypertensive patients: an exponential decay curve analysis.

Authors:  Takaaki Nakatsu; Shinji Toyonaga; Keiichi Mashima; Yoko Yuki; Aya Nishitani; Hiroko Ogawa; Toru Miyoshi; Satoshi Hirohata; Reishi Izumi; Shozo Kusachi
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

4.  Cilnidipine suppresses podocyte injury and proteinuria in metabolic syndrome rats: possible involvement of N-type calcium channel in podocyte.

Authors:  Yu-Yan Fan; Masakazu Kohno; Daisuke Nakano; Hiroyuki Ohsaki; Hiroyuki Kobori; Diah Suwarni; Naro Ohashi; Hirofumi Hitomi; Katsuhiko Asanuma; Takahisa Noma; Yasuhiko Tomino; Toshiro Fujita; Akira Nishiyama
Journal:  J Hypertens       Date:  2010-05       Impact factor: 4.844

5.  Long-term blockade of L/N-type Ca(2+) channels by cilnidipine ameliorates repolarization abnormality of the canine hypertrophied heart.

Authors:  A Takahara; Y Nakamura; H Wagatsuma; S Aritomi; A Nakayama; Y Satoh; Y Akie; A Sugiyama
Journal:  Br J Pharmacol       Date:  2009-09-28       Impact factor: 8.739

6.  N-type calcium channel inhibition with cilnidipine elicits glomerular podocyte protection independent of sympathetic nerve inhibition.

Authors:  Bai Lei; Daisuke Nakano; Yoshihide Fujisawa; Ya Liu; Hirofumi Hitomi; Hiroyuki Kobori; Hirohito Mori; Tsutomu Masaki; Katsuhiko Asanuma; Yasuhiko Tomino; Akira Nishiyama
Journal:  J Pharmacol Sci       Date:  2012-07-21       Impact factor: 3.337

7.  1,4-dihydropyridines: the multiple personalities of a blockbuster drug family.

Authors:  Mauro Cataldi; Fiorentina Bruno
Journal:  Transl Med UniSa       Date:  2012-10-11

Review 8.  Calcium channel blocker in patients with chronic kidney disease.

Authors:  Shoko Ohno; Akira Ishii; Motoko Yanagita; Hideki Yokoi
Journal:  Clin Exp Nephrol       Date:  2021-11-08       Impact factor: 2.801

Review 9.  N-type calcium channel and renal injury.

Authors:  Lei Bai; Shichao Sun; Yao Sun; Fujun Wang; Akira Nishiyama
Journal:  Int Urol Nephrol       Date:  2022-04-13       Impact factor: 2.266

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.